|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm diagnosed de novo or developed from essential thrombocythemia (ET) or polycythemia vera (PV).
|
22793267 |
2013 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm characterized by clonal myeloproliferation, dysregulated kinase signaling, and release of abnormal cytokines.
|
25232060 |
2014 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival.
|
26181658 |
2015 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelofibrosis (MF) and polycythemia vera (PV) are BCR-ABL1-negative myeloproliferative neoplasms associated with somatic hematopoietic stem cell mutations leading to over activation of JAK-STAT signaling.
|
27017614 |
2016 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary myelofibrosis is a unique entity among BCR-ABL-negative myeloproliferative diseases, manifesting as bone marrow fibrosis and pancytopenia.
|
27539616 |
2017 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelofibrosis is a BCR-ABL-negative myeloproliferative neoplasm characterized by abnormal hematopoiesis.
|
27672139 |
2017 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary myelofibrosis (PMF) is a rare chronic BCR-ABL1-negative myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, inefficient hematopoiesis, and shortened survival.
|
27756071 |
2016 |
|
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Primary myelofibrosis (PMF) is one of the classic BCR-ABL1 negative myeloproliferative neoplasms (MPN).
|
29256926 |
2018 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelofibrosis (MF) is a clinical manifestation of chronic BCR-ABL1-negative chronic myeloproliferative neoplasms.
|
29562644 |
2018 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ABSTRACT: Background The BCR-ABL-negative myeloproliferative neoplasms, i.e., polycythemia vera, essential thrombocythemia (ET), and myelofibrosis (MF), are characterized by mutations in JAK2, CALR, or MPL.
|
30889303 |
2019 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
After 5 months, BCR-ABL fusion signals decreased to 5%, and myelofibrosis improved from MF Grade 2 to 1; she then underwent allogeneic bone marrow transplantation from an unrelated donor.
|
30879266 |
2019 |
|
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As the second most common mutation in BCR/ABL-negative MPNs, CALR mutation has been included in the latest World Health Organization (WHO) classification criteria as one of the main diagnostic criteria for both essential thrombocythemia (ET) and PMF.
|
29560522 |
2018 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCR-ABL1-positive or PDGFRB-rearranged) and also assist in specific treatment selection (e.g. lenalidomide therapy is active in MF associated with del(5q).
|
19141119 |
2009 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCR-ABL1-negative MPN is a subcategory that includes primary myelofibrosis (MF), post-essential thrombocythemia MF, and post-polycythemia vera MF.
|
28499938 |
2017 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCR-ABL1-negative myeloproliferative neoplasms (MPNs) are clonal stem cell disorders defined by proliferation of one or more myeloid lineages, and carry an increased risk of vascular events and progression to myelofibrosis and leukemia.
|
28543980 |
2017 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chromosomal deletions of band 13q14 occur recurrently in BCR/ABL negative chronic myeloproliferative disorders (CMPD), including myelosclerosis with myeloid metaplasia (MMM), polycythemia vera (PV), essential thrombocythemia (ET), juvenile chronic myeloid leukemia (JCML), and the so-called BCR/ABL- chronic myeloid leukemia (CML).
|
8527391 |
1995 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clonal hematologic diseases of the blood such as polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL negative Myeloproliferative Neoplasms (MPN).
|
28914569 |
2017 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparative genomic hybridization (CGH), using oligo arrays with either 44,000 or 105,000 oligonucleotides, was performed on granulocyte-derived DNA from 71 patients with BCR-ABL-negative classic myeloproliferative neoplasms (MPNs): 32 primary myelofibrosis (PMF), 26 polycythemia vera (PV) and 13 essential thrombocythemia (ET).
|
18937974 |
2009 |
|
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic lesions such as JAK2 mutations and BCR-ABL translocation are often mutually exclusive in MPN patients and lead to essential thrombocythemia, polycythemia vera, or myelofibrosis or chronic myeloid leukemia, respectively.
|
28335073 |
2017 |
|
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In 1960, Nowell and Hungerford discovered an invariable association between the Philadelphia chromosome (subsequently shown to harbor the causal BCR-ABL1 mutation) and CML; accordingly, the term MPN is primarily reserved for PV, ET, and PMF, although it includes other related clinicopathologic entities, according to the World Health Organization (WHO) classification system.
|
26492355 |
2016 |
|
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the first case (female, aged 65, in blastic transformation which developed one year after the initial diagnosis of myelofibrosis), a t(14;22) (q32;q11) was found in association with several other chromosomal abnormalities [48,XX,+X,+5,del(5) (q12q32),+8,der(9)t(9;11)(q32;q11),-11]; molecular analysis demonstrated the presence of a BCR-ABL chimeric gene and mRNA transcript of the b2-a2 type.
|
8908174 |
1996 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
|
25520049 |
2014 |
|
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, the detection of BCR-ABL translocation appears to be crucial especially in the case of treated CIMF with an atypical course to identify CML before acute transformation.
|
18448166 |
2008 |
|
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most affected patients suffer from the classic BCR/ABL1-negative myeloproliferative disorders (MPD), especially polycythemia vera (74% of n = 506), but a subset of people with essential thrombocythemia (36% of n = 339) or myelofibrosis with myeloid metaplasia (44% of n = 127) bear the identical mutation, as do a few individuals with myelodysplastic syndromes or an atypical myeloid disorder (7% of n = 556).
|
16321848 |
2006 |
|
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Myeloproliferative neoplasms (MPN) that do not contain the BCR-ABL1 mutation include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
|
22035746 |
2011 |